The Motley Fool··Jonathan PoncianoPalvella Stock Soars 340% as COO Executes Pre-Planned Share Sale
Palvella COO sells ~$508K in shares via pre-planned trading arrangement amid 340% annual surge, driven by strong Phase 3 QTORIN rapamycin data and upcoming NDA submission.
PVLAbiotechclinical-stage